From 14a7fb7c27f130fb49cdf79a1adea9102ccc9e98 Mon Sep 17 00:00:00 2001 From: John Konecny <24961694+jfkonecn@users.noreply.github.com> Date: Mon, 24 Feb 2025 10:21:24 -0500 Subject: [PATCH] a --- src/main/webapp/app/config/constants.tsx | 2 +- .../webapp/app/pages/newsPage/NewsList.tsx | 1 - .../webapp/app/pages/newsPage/NewsPage.tsx | 2 +- .../app/pages/newsPage/NewsPageContent.tsx | 4 +- ...ontent022025.tsx => NewsContent022525.tsx} | 51 +++++++++++++------ ...sContent022025.md => NewsContent022525.md} | 20 +++++--- 6 files changed, 53 insertions(+), 27 deletions(-) rename src/main/webapp/app/pages/newsPage/code-generated/{NewsContent022025.tsx => NewsContent022525.tsx} (80%) rename src/main/webapp/app/pages/newsPage/markdown/{NewsContent022025.md => NewsContent022525.md} (58%) diff --git a/src/main/webapp/app/config/constants.tsx b/src/main/webapp/app/config/constants.tsx index d95031af8..0d32c0f4a 100644 --- a/src/main/webapp/app/config/constants.tsx +++ b/src/main/webapp/app/config/constants.tsx @@ -866,7 +866,7 @@ export type DataRelease = { }; export const DATA_RELEASES: DataRelease[] = [ - { date: '02302025', version: 'v4.26' }, + { date: '02252025', version: 'v4.26' }, { date: '01302025', version: 'v4.25' }, { date: '12192024', version: 'v4.24' }, { date: '11262024', version: 'v4.23' }, diff --git a/src/main/webapp/app/pages/newsPage/NewsList.tsx b/src/main/webapp/app/pages/newsPage/NewsList.tsx index 00db26e9e..7582ee5cf 100644 --- a/src/main/webapp/app/pages/newsPage/NewsList.tsx +++ b/src/main/webapp/app/pages/newsPage/NewsList.tsx @@ -19,7 +19,6 @@ import HashLink from 'app/shared/links/HashLink'; import { RouterStore } from 'mobx-react-router'; import { observable } from 'mobx'; import { observer } from 'mobx-react'; -import NewsContent01302025 from './code-generated/NewsContent01302025'; export type NewsListProps = { date: string; diff --git a/src/main/webapp/app/pages/newsPage/NewsPage.tsx b/src/main/webapp/app/pages/newsPage/NewsPage.tsx index cd7fced2a..efe908705 100644 --- a/src/main/webapp/app/pages/newsPage/NewsPage.tsx +++ b/src/main/webapp/app/pages/newsPage/NewsPage.tsx @@ -86,7 +86,7 @@ export default class NewsPage extends React.Component<{
- + diff --git a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx index 442ac85f8..98c4446e3 100644 --- a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx +++ b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx @@ -45,7 +45,7 @@ import { PMALink } from 'app/shared/links/PMALink'; import OptimizedImage from 'app/shared/image/OptimizedImage'; import { AnnotationColumnHeaderType } from './ChangedAnnotationListItem'; import { linkableMutationName, convertGeneInputToLinks } from './Util'; -import NewsContent022025 from './code-generated/NewsContent022025'; +import NewsContent022025 from './code-generated/NewsContent022525'; export type ChangedAnnotation = { content: (ElementType | ElementType[])[][]; @@ -303,7 +303,7 @@ const EVIDENCE_COLUMN_SEPARATOR = '; '; // https://stackoverflow.com/questions/41947168/is-it-possible-to-use-keyof-operator-on-literals-instead-of-interfaces export const NEWS_BY_DATE: { [date: string]: NewsData } = { - '02282025': { + '02252025': { rawComponent: , }, '01302025': { diff --git a/src/main/webapp/app/pages/newsPage/code-generated/NewsContent022025.tsx b/src/main/webapp/app/pages/newsPage/code-generated/NewsContent022525.tsx similarity index 80% rename from src/main/webapp/app/pages/newsPage/code-generated/NewsContent022025.tsx rename to src/main/webapp/app/pages/newsPage/code-generated/NewsContent022525.tsx index 60745e394..993b7d363 100644 --- a/src/main/webapp/app/pages/newsPage/code-generated/NewsContent022025.tsx +++ b/src/main/webapp/app/pages/newsPage/code-generated/NewsContent022525.tsx @@ -6,7 +6,7 @@ import { } from 'app/shared/utils/UrlUtils'; import { NewlyAddedGenesListItem } from 'app/pages/newsPage/NewlyAddedGenesListItem'; -export default function NewsContent022025() { +export default function NewsContent022525() { return ( <>
    @@ -39,11 +39,14 @@ export default function NewsContent022025() { Pancreatic Cancer - Drug(s) promoted in OncoKB™: Erdafitnib (Level 2, - previously Level 4) + Drug(s) promoted in OncoKB™:
    + Erdafitnib (Level 2, previously Level 4)
    - Drug(s) remaining in OncoKB™: Fexagratinib (Level 4) +
    + Drug(s) remaining in OncoKB™: +
    + Fexagratinib (Level 4) 4 2 @@ -62,11 +65,14 @@ export default function NewsContent022025() { Pancreatic Cancer - Drug(s) promoted in OncoKB™: Erdafitnib (Level 2, - previously Level 4) + Drug(s) promoted in OncoKB™: +
    + Erdafitnib (Level 2, previously Level 4) +

    + Drug(s) remaining in OncoKB™:
    - Drug(s) remaining in OncoKB™: Fexagratinib (Level 4) + Fexagratinib (Level 4) 4 2 @@ -85,12 +91,14 @@ export default function NewsContent022025() { Non-Small Cell Lung Cancer - Drug(s) promoted in OncoKB™: Erdafitnib (Level 2, - previously Level 4) + Drug(s) promoted in OncoKB™:
    + Erdafitnib (Level 2, previously Level 4)
    - Drug(s) remaining in OncoKB™: Fexagratinib, - Lirafugratinib (Level 4) +
    + Drug(s) remaining in OncoKB™: +
    + Fexagratinib, Lirafugratinib (Level 4) 4 2 @@ -110,11 +118,14 @@ export default function NewsContent022025() { Non-Small Cell Lung Cancer - Drug(s) promoted in OncoKB™: Erdafitnib (Level 2, - previously Level 4) + Drug(s) promoted in OncoKB™: +
    + Erdafitnib (Level 2, previously Level 4) +

    + Drug(s) remaining in OncoKB™:
    - Drug(s) remaining in OncoKB™: Fexagratinib (Level 4) + Fexagratinib (Level 4) 4 2 @@ -171,10 +182,20 @@ export default function NewsContent022025() {
+

diff --git a/src/main/webapp/app/pages/newsPage/markdown/NewsContent022025.md b/src/main/webapp/app/pages/newsPage/markdown/NewsContent022525.md similarity index 58% rename from src/main/webapp/app/pages/newsPage/markdown/NewsContent022025.md rename to src/main/webapp/app/pages/newsPage/markdown/NewsContent022525.md index dfc35674a..ab3e4f10f 100644 --- a/src/main/webapp/app/pages/newsPage/markdown/NewsContent022025.md +++ b/src/main/webapp/app/pages/newsPage/markdown/NewsContent022525.md @@ -1,11 +1,11 @@ - Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration -| Gene | Mutation | Cancer Type | Level-associated Drug(s) in OncoKB™ | Previous Level | Updated Level | Evidence | -| :---- | :------------------ | :------------------------- | :-------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- | -| FGFR1 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)

_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | -| FGFR2 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)

_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | -| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)

_Drug(s) remaining in OncoKB™:_ Fexagratinib, Lirafugratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | -| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)

_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | +| Gene | Mutation | Cancer Type | Level-associated Drug(s) in OncoKB™ | Previous Level | Updated Level | Evidence | +| :---- | :------------------ | :------------------------- | :---------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- | +| FGFR1 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_
Erdafitnib (Level 2, previously Level 4\)

_Drug(s) remaining in OncoKB™:_
Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | +| FGFR2 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_
Erdafitnib (Level 2, previously Level 4\)

_Drug(s) remaining in OncoKB™:_
Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | +| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_
Erdafitnib (Level 2, previously Level 4\)

_Drug(s) remaining in OncoKB™:_
Fexagratinib, Lirafugratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | +| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_
Erdafitnib (Level 2, previously Level 4\)

_Drug(s) remaining in OncoKB™:_
Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | - Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence) @@ -13,8 +13,14 @@ | :---- | :--- | :------- | :---------------- | :---------------------------------- | :---------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | | 1 | BRAF | V600E | Colorectal Cancer | Encorafenib \+ Cetuximab (Level 1\) | Encorafenib \+ Cetuximab \+ FOLFOX Regimen (Level 1\) | [FDA approval of encorafenib with cetuximab and mFOLFOX6](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf); PMID: [39863775](https://pubmed.ncbi.nlm.nih.gov/39863775/) | -- Addition of 4 new genes: +#### + +- Addition of 8 new genes: - ALOX5 - APEX1 + - CBLB + - DHX15 + - POLH - RPS6KB1 - TACSTD2 + - WEE1